Transit Time and Bacterial Overgrowth Using SmartPill Capsule

NATerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Small Bowel Bacterial OvergrowthGastrointestinal DiseasesStomach DiseasesDigestive System Diseases
Interventions
DRUG

Xifaxan

Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.

DEVICE

SmartPill

The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.

PROCEDURE

Lactulose hydrogen breath test (H_2BT)

A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.

Trial Locations (1)

85259

Mayo Clinic Arizona, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

The SmartPill Corporation

INDUSTRY

lead

Mayo Clinic

OTHER